AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowAbbVie (ABBV) adjusted its 2026 profit forecast downwards due to the acquisition of Apogee Therapeutics. The company reported second-quarter earnings that exceeded analyst expectations. The updated guidance reflects the financial implications of the acquisition, affecting projected profitability. This revision is significant for investors as it impacts future earnings expectations and may influence AbbVie's stock performance.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
- AbbVie (ABBV) Stock May Move 4.2% on July 31 Earnings Report
- AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
- Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
- AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
